Sensorion SA (ALSEN.PA)
EUR 0.64
(-6.16%)
EUR 0.64
(-6.16%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -22.31 Million EUR | 0.48% |
| 2022 | -28.1 Million EUR | -45.24% |
| 2021 | -19.35 Million EUR | -71.39% |
| 2020 | -11.29 Million EUR | 15.23% |
| 2019 | -13.31 Million EUR | -8.23% |
| 2018 | -12.3 Million EUR | -28.09% |
| 2017 | -9.6 Million EUR | -5.49% |
| 2016 | -9.1 Million EUR | -71.1% |
| 2015 | -5.32 Million EUR | -85.85% |
| 2014 | -2.86 Million EUR | -92.12% |
| 2013 | -1.49 Million EUR | -53.23% |
| 2012 | -972.84 Thousand EUR | -51.16% |
| 2011 | -643.6 Thousand EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 119 Thousand EUR | 0.0% |
| 2023 Q2 | -14.83 Million EUR | 0.0% |
| 2023 Q4 | -10.11 Million EUR | 0.0% |
| 2023 FY | -27.96 Million EUR | 0.48% |
| 2022 Q2 | -14.09 Million EUR | 0.0% |
| 2022 FY | -28.1 Million EUR | -45.24% |
| 2022 Q4 | -14 Million EUR | 0.0% |
| 2021 Q2 | -7.74 Million EUR | 0.0% |
| 2021 Q4 | -11.6 Million EUR | 0.0% |
| 2021 FY | -19.35 Million EUR | -71.39% |
| 2020 Q4 | -5.72 Million EUR | 0.0% |
| 2020 Q2 | -5.56 Million EUR | 0.0% |
| 2020 FY | -11.29 Million EUR | 15.23% |
| 2019 Q2 | -6.47 Million EUR | 0.0% |
| 2019 FY | -13.31 Million EUR | -8.23% |
| 2019 Q4 | -6.84 Million EUR | 0.0% |
| 2018 Q2 | -6.13 Million EUR | 0.0% |
| 2018 Q4 | -6.17 Million EUR | 0.0% |
| 2018 FY | -12.3 Million EUR | -28.09% |
| 2017 FY | -9.6 Million EUR | -5.49% |
| 2017 Q4 | -5.14 Million EUR | 0.0% |
| 2017 Q2 | -4.46 Million EUR | 0.0% |
| 2016 FY | -9.1 Million EUR | -71.1% |
| 2016 Q2 | -4.33 Million EUR | 0.0% |
| 2016 Q4 | -4.77 Million EUR | 0.0% |
| 2015 FY | -5.32 Million EUR | -85.85% |
| 2015 Q4 | -3.79 Million EUR | 0.0% |
| 2015 Q2 | -1.53 Million EUR | 0.0% |
| 2014 FY | -2.86 Million EUR | -92.12% |
| 2014 Q4 | -1.83 Million EUR | -138.07% |
| 2014 Q3 | -770.24 Thousand EUR | 29.2% |
| 2014 Q2 | -1.08 Million EUR | -41.25% |
| 2014 Q1 | -770.24 Thousand EUR | 0.0% |
| 2013 Q3 | -411.68 Thousand EUR | 0.0% |
| 2013 FY | -1.49 Million EUR | -53.23% |
| 2013 Q4 | -770.24 Thousand EUR | -87.09% |
| 2013 Q1 | -411.68 Thousand EUR | 0.0% |
| 2013 Q2 | -411.68 Thousand EUR | 0.0% |
| 2012 Q4 | -411.68 Thousand EUR | -66.79% |
| 2012 FY | -972.84 Thousand EUR | -51.16% |
| 2012 Q1 | -246.83 Thousand EUR | 0.0% |
| 2012 Q2 | -246.83 Thousand EUR | 0.0% |
| 2012 Q3 | -246.83 Thousand EUR | 0.0% |
| 2011 FY | -643.6 Thousand EUR | 0.0% |
| 2011 Q4 | -246.83 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -553.887% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 82.484% |
| Adocia SA | -17.62 Million EUR | -26.607% |
| Aelis Farma SA | -6.46 Million EUR | -245.312% |
| Biophytis S.A. | -14.33 Million EUR | -55.659% |
| Advicenne S.A. | -6.45 Million EUR | -245.526% |
| genOway Société anonyme | 2.06 Million EUR | 1180.263% |
| IntegraGen SA | -183.77 Thousand EUR | -12040.517% |
| Medesis Pharma S.A. | -4.22 Million EUR | -427.52% |
| Neovacs S.A. | -6.9 Million EUR | -222.989% |
| NFL Biosciences SA | -4.43 Million EUR | -403.578% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -2766.817% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -611.151% |
| Theranexus Société Anonyme | -7.64 Million EUR | -191.883% |
| TME Pharma N.V. | -5.62 Million EUR | -296.704% |
| Valbiotis SA | -7.16 Million EUR | -211.601% |
| TheraVet SA | -2.17 Million EUR | -925.725% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -9.97% |
| argenx SE | -417.15 Million EUR | 94.652% |
| BioSenic S.A. | -7.04 Million EUR | -216.912% |
| Celyad Oncology SA | -8.45 Million EUR | -163.813% |
| DBV Technologies S.A. | -85.24 Million EUR | 73.828% |
| Galapagos NV | -88.26 Million EUR | 74.723% |
| Genfit S.A. | -26.58 Million EUR | 16.062% |
| GeNeuro SA | -14.35 Million EUR | -55.396% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -39.502% |
| Innate Pharma S.A. | -12.66 Million EUR | -76.104% |
| Inventiva S.A. | -102.7 Million EUR | 78.278% |
| MaaT Pharma SA | -19.94 Million EUR | -11.872% |
| MedinCell S.A. | -20.97 Million EUR | -6.358% |
| Nanobiotix S.A. | -26.77 Million EUR | 16.686% |
| Onward Medical N.V. | -35.46 Million EUR | 37.088% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -390.43% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 2.938% |
| Oxurion NV | -12.11 Million EUR | -84.233% |
| Pharming Group N.V. | -4.87 Million EUR | -357.228% |
| Poxel S.A. | -28.76 Million EUR | 22.436% |
| GenSight Biologics S.A. | -29.69 Million EUR | 24.87% |
| Transgene SA | -30.01 Million EUR | 25.661% |
| Financière de Tubize SA | -2.14 Million EUR | -940.62% |
| UCB SA | 604 Million EUR | 103.694% |
| Valneva SE | -82.08 Million EUR | 72.821% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 22.632% |